ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406

Phase 1AK0406Positive

AI Analysis

Summary

ArkBio completed dosing of all cohorts in an Australian Phase 1 trial of AK0406, a long-acting antiviral-Fc conjugate drug for influenza prophylaxis. This represents a routine trial milestone with no efficacy data or regulatory decision information disclosed.

Clinical Trial Data

Phase

Phase 1

Outcome Details

all cohorts of healthy volunteers dosed

Importance:4/10

Sentiment:

0.50

Phase 1influenzaantiviralAustraliatrial milestone

Related Companies

$HCWC

Read the original article

Published by PR Newswire Biotech on July 24, 2026 1:00 AM

Read Original